

Press release

1. February 2021

COVID-19 vaccine production at Allergopharma

- **To increase vaccine production in Germany, the company Allergopharma from Reinbek near Hamburg will soon be producing the COVID-19 vaccine of Mainz company BioNTech.**

Reinbek, 1st February 2021 – All citizens should receive an invite to have the vaccination for the COVID-19-Virus by the end of the summer. To make sure this is realizable, vaccine production must be significantly increased. The company Allergopharma will soon be producing the COVID-19 vaccine of the Mainz company BioNTech in new, ultra-modern production facilities in Reinbek near Hamburg (see photo).

Allergopharma is a subsidiary of Dermapharm Holding, which has entered into a cooperation and supplier agreement with BioNTech and has been involved in the production of the COVID-19 vaccine since October. The additional capacity levels in Reinbek are higher than those of Dermapharm in Brehna near Leipzig.

The product portfolio of Allergopharma includes medicinal products used in the diagnosis of allergies and allergen-specific immunotherapy of respiratory diseases. As the only company in this field, Allergopharma develops and produces its products exclusively in Germany.



Allergopharma

Allergopharma GmbH & Co. KG, part of Dermapharm AG, is one of the leading companies for allergen-specific immunotherapy (AIT) and has more than 50 years' experience in the field. The product portfolio includes the areas of diagnostics and allergy-specific immunotherapy of type I allergies such as allergic rhinitis (e.g. hay fever) and allergic asthma. With many years of expertise, scientific excellence and corporate responsibility, more than 300 employees are working across the globe to be able to provide doctors with first-class therapy options and to enable allergy sufferers to lead a fulfilled life. All products are produced in Reinbek near Hamburg under ultra-pure, sterile conditions.

